Mounjaro
The price ain’t right: Lilly
Positive funding recommendation for Mounjaro came with “unviable and unsustainable conditions”, sponsor says Eli Lilly is calling for “wholesale changes” to be made to the PBS (Pharmaceutical Benefits Scheme) after withdrawing its application …
Mounjaro contraception advice updated
Product information to recommend patients taking Mounjaro switch to non-oral contraceptives for four weeks after each dose An investigation by the Therapeutic Goods Administration (TGA) into the potential for reduced effectiveness of oral contraceptives during initiation …
World News – 21 August 2025
Cryptocurrency payments system to ease cashflow constraints on small pharmacies; British pharmacy bodies seek government protection from Mounjaro price hikes; ‘Hair Lifting Shampoo’ to hit pharmacy shelves Tampa, Florida, US: …
Mounjaro KwikPen transition complete: Lilly
Eli Lilly confirms that Mounjaro (tirzepatide) will no longer be available in vial presentations, after transitioning the product to a multi-dose, pre-filled pen Mounjaro manufacturer, Eli Lilly, has informed the …
No fifth dose in Mounjaro KwikPen: Lilly
Patients using Eli Lilly’s Mounjaro are being reminded that the KwikPen injection devices should be discarded after four doses Residual liquid leftover after patients have injected their fourth dose of …
Eli Lilly clarifies Mounjaro availability
Manufacturer moves to correct inaccurate reporting on the availability of Mounjaro Mandatory shortage reporting requirements for glucagon-like peptide-1 receptor agonist (GLP-1 RA) medicines is causing confusion about the availability …
‘Unexpected demand’ hits Mounjaro single-use vials
Supplies of single-use vials of diabetes and chronic weight management medication, Mounjaro, are set to be limited over the coming months Pharmaceutical company, Eli Lilly, is forecasting that supplies of …
Petition seeks rethink of GLP-1 RAs compounding ban
Politicians are being urged to reconsider the decision to ban the compounding of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) until supply issues ease Patients are calling for the government’s decision …
Ozempic compounding ban no ‘knee-jerk’ reaction
Department defends recommendation to ban the compounding of semaglutide and tirepatide medications Moves to prohibit pharmacists from compounding replicas of Ozempic (semaglutide) and Mounjaro (tirepatide) were not a “knee-jerk response” …
Compounding ban ‘a significant public health concern’
Government urged to roll back its ban on compounding weight loss drugs Banning the compounding of glucagon-like peptide-2 receptor agonists (GLP-1RAs) medications will limit patient access to the weight loss …
Government acts on compounding concerns
Compounding exemptions for diabetes medications, Ozempic and Mounjaro, will be removed from 1 October, minister reveals Compounding pharmacies will be barred from producing replicas of Ozempic (semaglutide) and Mounjaro (tirazapetide) …
Severe reactions linked to ‘compounded’ Ozempic
Patient violently ill and vomiting blood after taking illegally compounded Ozempic from an online pharmacy Products being sold as compounded Ozempic (semaglutide) and Mounjaro (tirzepatide) are being linked to severe side …